Is this your firm? Get featured or correct your listing →
At a glance
Catalio Capital Management appears in 4 funding rounds tracked by ValueAddVC since 2026, leading 2. Its most frequent sector in these rounds is Health & Biotech, and its most recent tracked deal was BigHat Biosciences' $75M Series C round (Sep 24, 2026).
Strategy
Recent changes
- Sep 24, 2026Sep 24, 2026Invested in BigHat Biosciences (Series C, $75M) BioSpace
- Sep 23, 2026Sep 23, 2026Invested in Basecamp Research (Series C, $140M) PR Newswire
- Sep 23, 2026Sep 23, 2026Invested in Enveda Biosciences (Series E, $311M) Tech Startups
- Sep 22, 2026Sep 22, 2026Invested in Evvy (Series B, $40M) AlleyWatch
Portfolio
6 totalRecent Investment Activity
4Track record: led 2 and participated in 2 of 4 tracked venture rounds · 4 in the last 12 months · led 1 Series E, 1 Series B
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | BigHat Biosciences | Series C | Participated | $75M | — | DFJ GrowthLeadPremji InvestLeadCatalio Capital ManagementLG Technology Ventures8VCAndreessen HorowitzEli Lilly and CompanyMerck Global Health Innovation FundQuadrille CapitalGRIDS CapitalIntermountain VenturesSection 32Sigmas GroupAmgen VenturesAlexandria Venture InvestmentsDiscovery Ventures | BioSpace |
| Sep 23, 2026 | Basecamp Research | Series C | Participated | $140M | — | Section 32LeadMenlo VenturesNvidiaNATO Innovation FundCatalio Capital ManagementTrue VenturesRockefeller Foundation | PR Newswire |
| Sep 23, 2026 | Enveda Biosciences | Series E | Led | $311M | ~$2B | Tech Startups | |
| Sep 22, 2026 | Evvy | Series B | Led | $40M | — | Catalio Capital ManagementLeadRethink ImpactMuse CapitalAlumni VenturesGeneral CatalystLeft Lane CapitalBBG VenturesFlywheel VenturesLabcorp Venture FundAmboy Street VenturesIngeborg+1 more | AlleyWatch |
Sector / Stage Activity
Co-Investors
12Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Sep 24, 2026BigHat Biosciences Raises $75M To Scale AI Antibody DesignBigHat Biosciences closed a $75 million Series C co-led by DFJ Growth and Premji Invest, taking total funding to $223 million as its AI-designed antibody-drug conjugate enters a Phase 1 trial for gastric cancer.→
- Sep 23, 2026Basecamp Research Raises $140M Led By S32Basecamp Research raised a $140 million Series C led by Bill Maris's S32, with Nvidia and Menlo Ventures' Anthology Fund among the backers, to train a new generation of its EDEN foundation models and push AI-designed therapeutics into clinical development.→
- Sep 23, 2026Enveda Biosciences Raises $311M Series E At $2BBoulder-based Enveda Biosciences raised a $311 million Series E led by Catalio Capital Management at roughly a $2 billion valuation, funding its AI platform that mines natural compounds for new drug candidates.→
- Sep 3, 2026Superluminal Raises $60M for AI-Designed Obesity PillThe Boston biotech's Series B, backed by Nvidia and Eli Lilly among others, funds Phase 1 trials of an oral MC4R agonist for rare genetic obesity designed by its de novo drug-discovery AI platform.→
Catalio Capital Management FAQ
What companies has Catalio Capital Management invested in?
Catalio Capital Management's portfolio includes BigHat Biosciences, Enveda Biosciences, Basecamp Research, Evvy, Flourish, Iambic.
Who does Catalio Capital Management co-invest with most?
In the rounds Value Add tracks, Catalio Capital Management most often invests alongside Lux Capital (2 shared deals), Nvidia (2 shared deals), 8VC (1 shared deal), Abingworth (1 shared deal), Alumni Ventures (1 shared deal).
Sources & methodologyshow
- PR Newswireprimary source1 fact
- BioSpaceresearch database1 fact
- AlleyWatchValue Add VC data1 fact
- Tech StartupsValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.